EKSO · Ekso Bionics Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $5.95M | $8.41M | $9.20M | $6.70M | $4.50M | $3.81M |
| Gross Profit | $6.84M | $9.51M | $9.08M | $6.21M | $6.75M | $5.07M |
| R&D | $3.03M | $3.87M | $5.03M | $3.63M | $2.75M | $2.47M |
| SG&A | $9.99M | $8.79M | $10.69M | $10.99M | $10.52M | $7.70M |
| Total Operating Expenses | $20.17M | $19.97M | $24.19M | $21.77M | $20.58M | $18.36M |
| D&A | $1.57M | $1.61M | $1.70M | $887.0K | $561.0K | $620.0K |
| Operating Income | ($13.33M) | ($10.46M) | ($15.11M) | ($15.56M) | ($13.83M) | ($13.29M) |
| Interest Expense | $309.0K | $269.0K | $302.0K | $156.0K | $113.0K | $139.0K |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | ($11.70M) | ($11.33M) | ($15.20M) | ($15.08M) | ($9.76M) | ($15.82M) |
| EPS - Basic | ($4.91) | ($126.00) | ($247.50) | ($261.00) | ($180.00) | ($497.25) |
| EPS - Diluted | ($8.43) | - | ($247.50) | ($261.00) | ($198.00) | ($497.25) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.17M | $6.49M | $8.64M | $20.52M | $40.41M | $12.86M |
| Accounts Receivable | $7.31M | $7.24M | $5.64M | $4.63M | $4.66M | $3.39M |
| Inventory | $4.82M | $4.57M | $5.05M | $5.19M | $2.24M | $1.98M |
| Accounts Payable | $1.43M | $1.55M | $1.85M | $3.15M | $3.11M | $1.50M |
| Current Assets | $14.05M | $18.84M | $20.21M | $31.04M | $47.80M | $18.42M |
| Total Assets | $20.11M | $26.65M | $28.92M | $40.90M | $49.17M | $20.60M |
| Current Liabilities | $8.64M | $7.54M | $8.12M | $9.20M | $6.86M | $4.97M |
| Long-term Debt | - | - | - | - | $1.99M | $1.99M |
| Total Liabilities | $11.08M | $13.95M | $16.31M | $15.46M | $11.95M | $16.16M |
| Stockholders' Equity | $9.03M | $12.71M | $12.61M | $25.44M | $37.22M | $4.43M |
| Retained Earnings | ($262.40M) | ($250.47M) | ($239.15M) | ($223.95M) | ($208.87M) | ($199.10M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.80M) | ($9.85M) | ($12.05M) | ($14.69M) | ($11.16M) | ($8.76M) |
| Investing Cash Flow | ($188.0K) | ($37.0K) | ($157.0K) | ($5.17M) | ($59.0K) | $0 |
| Financing Cash Flow | $6.63M | $7.77M | $348.0K | $0 | $38.71M | $10.70M |
| CapEx | $188.0K | $37.0K | $157.0K | $194.0K | $59.0K | $0 |
| Free Cash Flow | ($11.99M) | ($9.88M) | ($12.21M) | ($14.88M) | ($11.21M) | ($8.76M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 1.03 | 0.87 | 0.80 | 0.99 | 1.15 | 0.55 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -58.2% | -42.5% | -52.6% | -36.9% | -19.9% | -76.8% |
| Return on equity | -129.6% | -89.2% | -120.6% | -59.3% | -26.2% | -356.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.63 | 2.50 | 2.49 | 3.37 | 6.97 | 3.70 |
| Quick ratio | 1.07 | 1.89 | 1.87 | 2.81 | 6.65 | 3.31 |
| Cash ratio | 0.14 | 0.86 | 1.06 | 2.23 | 5.89 | 2.59 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | 0.05 | 0.45 |
| Debt / Assets | - | - | - | - | 0.04 | 0.10 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -43.1x | -38.9x | -50.0x | -99.7x | -122.4x | -95.6x |
| Equity multiplier | 2.23 | 2.10 | 2.29 | 1.61 | 1.32 | 4.65 |
| Liabilities / Assets | 0.55 | 0.52 | 0.56 | 0.38 | 0.24 | 0.78 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | 1.23 | 1.84 | 1.82 | 1.29 | 2.01 | 1.93 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 296d | 198d | 200d | 283d | 182d | 189d |
| Days payable outstanding | 88d | 67d | 73d | 172d | 252d | 144d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 14.5x | 41.3x | 9.1x | 13.1x | 148.6x |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | -28.0% | 4.8% | 46.1% | -7.9% | 33.1% | -25.0% |
| Operating income growth (YoY) | -27.4% | 30.8% | 2.9% | -12.5% | -4.0% | 20.1% |
| Net income growth (YoY) | -3.2% | 25.5% | -0.8% | -54.4% | 38.3% | -30.4% |
| EPS growth (YoY) | - | - | 5.2% | -31.8% | 60.2% | -292400.0% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -21.3% | 19.1% | 17.9% | -32.7% | -28.1% | 44.7% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -29.0% | 0.8% | -50.5% | -31.6% | 739.4% | -34.8% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: General Industrial Machinery & Equipment, NEC
Comparing EKSO BIONICS HOLDINGS against the 5 most active filers in the same SIC group.